Skip to main content

Advertisement

SpringerLink
Log in

Metabolic abnormalities associated with HIV infection and antiretroviral therapy

  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

Although noted early in the HIV epidemic, metabolic abnormalities came to prominence when potent combination antiretroviral therapy was introduced. Complications associated with HIV infection and antiretroviral therapy include cardiovascular disease, lipid disorders, glucose metabolism disorders, adipose tissue disorders, bone metabolism disorders, and lactic acidosis. Metabolic complications have driven the discovery of new agents and classes of antiretrovirals, and have shaped guidelines for the management of HIV infection. However, significant uncertainty remains about pathogenesis and management. Substantial complexity exists in the treatment of these disorders, illustrated by the complex drugdrug interactions between lipid-lowering agents and antiretroviral regimens. Several important new developments include the association of a higher risk of cardiovascular events with the discontinuation of antiretroviral therapy or use of specific drugs like abacavir and didanosine. This article reviews the current understanding of metabolic abnormalities associated with HIV and its treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. US Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents: January 29, 2008. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed August 27, 2008.

  2. Dube MP, Stein JH, Aberg JA, et al.: Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003, 37:613–627.

    Article  PubMed  Google Scholar 

  3. DA Wohl, McComsey G, Tebas P, et al.: Current concepts in the diagnosis and management of metabolic complications of HIV and its therapy. Clin Infect Dis 2006, 43:645–653.

    Article  Google Scholar 

  4. Henry K, Melroe H, Huebusch J, et al.: Severe premature coronary artery disease with protease inhibitors [letter]. Lancet 1998, 351:1328.

    Article  PubMed  CAS  Google Scholar 

  5. Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group: Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003, 349:1993–2003.

    Article  Google Scholar 

  6. Mary-Krause M, Cotte L, Simon A, et al.; and the Clinical Epidemiology Group from the French Hospital Database: Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003, 17:2479–2486.

    Article  PubMed  Google Scholar 

  7. Klein D, Hurley L, Queensbury C, Sidney S: Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002, 30:471–477.

    PubMed  CAS  Google Scholar 

  8. Bozzette SA, Ake CF, Tam HK, et al.: Long-term survival and serious cardiovascular events in HIV-infected patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2008, 47:338–341.

    Article  PubMed  CAS  Google Scholar 

  9. D:A:D Study Group: Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008, 371:1417–1426.

    Article  CAS  Google Scholar 

  10. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, et al.: CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006, 355:2283–2296.

    Article  PubMed  CAS  Google Scholar 

  11. Grinspoon SK, Grunfeld C, Kotler DP, et al.: State of the Science Conference: initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation 2008, 118:198–210.

    Article  PubMed  Google Scholar 

  12. Grinspoon S, Carr A: Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005, 352:48–62.

    Article  PubMed  CAS  Google Scholar 

  13. Sax PE, Kumar P: Tolerability and safety of HIV protease inhibitors in adults. J Acquir Immune Def Syndr 2004, 37:1111–1124.

    Article  CAS  Google Scholar 

  14. van Leth F, Phanuphak P, Stroes E, et al.: Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 2004, 1:e19.

    Article  PubMed  CAS  Google Scholar 

  15. Gallant JE, Staszewski S, Pozniak AL, et al.: Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004, 292:191–201.

    Article  PubMed  CAS  Google Scholar 

  16. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486–2497.

    Article  Google Scholar 

  17. Drechsler H, Powderly WG: Switching effective antiretroviral therapy: a review. Clin Infect Dis 2002, 35:1219–1230.

    Article  PubMed  CAS  Google Scholar 

  18. Mobius U, Lubach-Ruitman M, Castro-Frenzel B, et al.: Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia. J Acquir Immune Defic Syndr 2005, 39:174–180.

    PubMed  Google Scholar 

  19. Aberg JA, Zackin RA, Brobst SW, et al.: A prospective, multicenter, randomized trial comparing the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Res Human Retroviruses 2005, 21:757–767.

    Article  CAS  Google Scholar 

  20. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al.: Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 2002, 16:569–577.

    Article  PubMed  CAS  Google Scholar 

  21. Gerber JG, Rosenkranz SL, Fichtenbaum CJ, et al.: Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS clinical trials group 5108 study. J Acquir Immune Defic Syndr 2005, 39:307–312.

    Article  PubMed  CAS  Google Scholar 

  22. Sekar VJ, Spinosa-Guzman S, Mariën K, et al.: Pharmacokinetic drug-drug interaction between the new HIV protease inhibitor darunavir (TMC114) and the lipid-lowering agent pravastatin [abstract 54]. Presented at the 8th International Workshop on Clinical Pharmacology of HIV Therapy. Budapest, Hungary: April 16–18, 2007.

  23. Kiser JJ, Gerber JG, Predhomme JA, et al.: Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr 2008, 47:570–578.

    Article  PubMed  CAS  Google Scholar 

  24. Standards of medical care in diabetes. Diabetes Care 2005, 28(Suppl 1):S4–S36.

  25. Brown TT, Li X, Cole SR, et al.: Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS 2005, 19:1375–1383.

    Article  PubMed  CAS  Google Scholar 

  26. Justman JE, Benning L, Danoff A, et al.: Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr 2003, 32:298–302.

    Article  PubMed  CAS  Google Scholar 

  27. Noor A, Flint OP, Mae JF, Parker RA: Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS 2006, 20:1813–1821.

    Article  PubMed  CAS  Google Scholar 

  28. Kratz M, Purnell JQ, Breen PA, et al.: Reduced adipogenic gene expression in thigh adipose tissue precedes human immunodeficiency virus-associated lipoatrophy. J Clin Endocrinol Metab 2008, 93:959–966.

    Article  PubMed  CAS  Google Scholar 

  29. Lichtenstein KA, Ward DJ, Morman AC, et al.: Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001, 15:1389–1398.

    Article  PubMed  CAS  Google Scholar 

  30. Hulgan T, Tebas P, Canter JA, et al.: Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy. J Infect Dis 2008, 197:858–866.

    Article  PubMed  CAS  Google Scholar 

  31. Dube MP, Parker RA, Tebas P, et al.: Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005, 19:1807–1818.

    PubMed  CAS  Google Scholar 

  32. van der Valk M, Gisolf EH, Reiss P, et al.: Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS 2001, 15:847–855.

    Article  PubMed  Google Scholar 

  33. Haubrich RH, Riddler S, DiRienzo G, et al.: Metabolic outcomes of ACTG 5142: a prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection [abstract 38]. Presented at the 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA; February 25–28, 2007.

  34. Brinkman K, Smeitink JA, Romijn JA, et al.: Mitochondrial toxicity induced by nucleoside analogue reverse transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral therapy lipodystrophy. Lancet 1999, 354:1112–1115.

    Article  PubMed  CAS  Google Scholar 

  35. Lee H, Hanes J, Johnson KA: Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry 2003, 42:14711–14719.

    Article  PubMed  CAS  Google Scholar 

  36. Carr A, Workman C, Smith DE, et al.: Abacavir substitution for thymidine nucleoside analogues in HIV-infected patients with lipoatrophy: a randomized controlled open-label multicenter 24 week study. JAMA 2002, 288:207–215.

    Article  PubMed  CAS  Google Scholar 

  37. McComsey GA, Ward DJ, Hessenthaler SM, et al.: Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virusinfected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis 2004, 38:263–270.

    Article  PubMed  CAS  Google Scholar 

  38. Carr A, Workman C, Carey D, et al.: No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomized, double-blind, placebo-controlled trial. Lancet 2004, 363:429–438.

    Article  PubMed  CAS  Google Scholar 

  39. Sutinen J, Walker UA, Häkkinen AM, et al.: Uridine for the treatment of HAART-associated lipodystrophy: a randomized, double-blind, placebo-controlled trial. Antivir Ther 2007, 12:97–105.

    PubMed  CAS  Google Scholar 

  40. Bacchetti P, Gripshover B, Grunfeld C, et al.: Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005, 40:121–131.

    Article  PubMed  Google Scholar 

  41. Roubenoff R, Weiss L, McDermott A, et al.: A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution. AIDS 1999, 13:1373–1375.

    Article  PubMed  CAS  Google Scholar 

  42. Hadigan C, Corcoran C, Basgoz N, et al.: Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA 2000, 284:472–477.

    Article  PubMed  CAS  Google Scholar 

  43. Falutz J, Allas S, Kotler D, et al.: A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS 2005, 19:1279–1287.

    Article  PubMed  CAS  Google Scholar 

  44. Cazanave C, Dupon M, Lavignolle-Aurillac V, et al.: Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS 2008, 22:395–402.

    PubMed  Google Scholar 

  45. Prior J, Burdge D, Maan E, et al.: Fragility fractures and bone mineral density in HIV positive women: a case-control population-based study. Osteoporos Int 2007, 18:1345–1353.

    Article  PubMed  CAS  Google Scholar 

  46. Mondy K, Yarasheski K, Powderly WG, et al.: Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 2003, 36:482–490.

    Article  PubMed  Google Scholar 

  47. McComsey GA, Kendall MA, Tebas P, et al.: Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS 2007, 21:2473–2482.

    Article  PubMed  CAS  Google Scholar 

  48. Wohl DA, Pilcher CD, Evans S, et al.: Absence of sustained hyperlactatemia in HIV-infected patients with risk factors for mitochondrial toxicity. J Acquir Immune Defic Syndr 2004, 35:274–278.

    Article  PubMed  Google Scholar 

  49. Brinkman K, Smeitink JA, Romijn JA, et al.: Mitochondrial toxicity induced by nucleoside analogue reverse transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral therapy lipodystrophy. Lancet 1999, 354:1112–1115.

    Article  PubMed  CAS  Google Scholar 

  50. Wester C, Okezie OA, Thomas AM, et al.: Higher-thanexpected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trial. J Acquir Immune Defic Syndr 2007, 46:318–22.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, University of Cincinnati College of Medicine, 231 Albert Sabin Way, PO Box 670560, Cincinnati, OH, 45267-0560, USA

    Carl J. Fichtenbaum

Authors
  1. Carl J. Fichtenbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carl J. Fichtenbaum.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fichtenbaum, C.J. Metabolic abnormalities associated with HIV infection and antiretroviral therapy. Curr Infect Dis Rep 11, 84–92 (2009). https://doi.org/10.1007/s11908-009-0012-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11908-009-0012-8

Keywords

Search

Navigation